Literature DB >> 25966493

Adipocyte Mineralocorticoid Receptor Activation Leads to Metabolic Syndrome and Induction of Prostaglandin D2 Synthase.

Riccardo Urbanet1, Aurelie Nguyen Dinh Cat1, Alessandra Feraco1, Nicolas Venteclef1, Soumaya El Mogrhabi1, Catalina Sierra-Ramos1, Diego Alvarez de la Rosa1, Gail K Adler1, Didier Quilliot1, Patrick Rossignol1, Francesco Fallo1, Rhian M Touyz1, Frédéric Jaisser2.   

Abstract

Metabolic syndrome is a major risk factor for the development of diabetes mellitus and cardiovascular diseases. Pharmacological antagonism of the mineralocorticoid receptor (MR), a ligand-activated transcription factor, limits metabolic syndrome in preclinical models, but mechanistic studies are lacking to delineate the role of MR activation in adipose tissue. In this study, we report that MR expression is increased in visceral adipose tissue in a preclinical mouse model of metabolic syndrome and in obese patients. In vivo conditional upregulation of MR in mouse adipocytes led to increased weight and fat mass, insulin resistance, and metabolic syndrome features without affecting blood pressure. We identified prostaglandin D2 synthase as a novel MR target gene in adipocytes and AT56, a specific inhibitor of prostaglandin D2 synthase enzymatic activity, blunted adipogenic aldosterone effects. Moreover, translational studies showed that expression of MR and prostaglandin D2 synthase is strongly correlated in adipose tissues from obese patients.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  aldosterone; obesity; prostaglandin D2 synthase 21kDa, brain; spironolactone

Mesh:

Substances:

Year:  2015        PMID: 25966493     DOI: 10.1161/HYPERTENSIONAHA.114.04981

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  23 in total

1.  What Is the Role of the Adipocyte Mineralocorticoid Receptor in the Metabolic Syndrome?

Authors:  Celso E Gomez-Sanchez
Journal:  Hypertension       Date:  2015-05-11       Impact factor: 10.190

Review 2.  Mineralocorticoid receptors in the pathogenesis of insulin resistance and related disorders: from basic studies to clinical disease.

Authors:  Guanghong Jia; Warren Lockette; James R Sowers
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2021-01-13       Impact factor: 3.619

3.  Role of Mineralocorticoid Receptor in Adipogenesis and Obesity in Male Mice.

Authors:  Daniel Ferguson; Irina Hutson; Eric Tycksen; Terri A Pietka; Kevin Bauerle; Charles A Harris
Journal:  Endocrinology       Date:  2020-02-01       Impact factor: 4.736

Review 4.  Primary Aldosteronism and Ischemic Heart Disease.

Authors:  Shivaraj Patil; Chaitanya Rojulpote; Aman Amanullah
Journal:  Front Cardiovasc Med       Date:  2022-05-23

Review 5.  Aldosterone in vascular and metabolic dysfunction.

Authors:  James M Luther
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-01       Impact factor: 2.894

6.  Lipocalin-2 derived from adipose tissue mediates aldosterone-induced renal injury.

Authors:  Wai Yan Sun; Bo Bai; Cuiting Luo; Kangmin Yang; Dahui Li; Donghai Wu; Michel Félétou; Nicole Villeneuve; Yang Zhou; Junwei Yang; Aimin Xu; Paul M Vanhoutte; Yu Wang
Journal:  JCI Insight       Date:  2018-09-06

Review 7.  The mineralocorticoid receptor-an emerging player in metabolic syndrome?

Authors:  Moe Thuzar; Michael Stowasser
Journal:  J Hum Hypertens       Date:  2021-02-01       Impact factor: 3.012

8.  Primary Aldosteronism Decreases Insulin Secretion and Increases Insulin Clearance in Humans.

Authors:  Gail K Adler; Gillian R Murray; Adina F Turcu; Hui Nian; Chang Yu; Carmen C Solorzano; Robert Manning; Dungeng Peng; James M Luther
Journal:  Hypertension       Date:  2020-03-16       Impact factor: 10.190

Review 9.  The enzymology of the human prostanoid pathway.

Authors:  Roger Gregory Biringer
Journal:  Mol Biol Rep       Date:  2020-05-19       Impact factor: 2.316

10.  Identification of Key Pathways and Genes in Obesity Using Bioinformatics Analysis and Molecular Docking Studies.

Authors:  Harish Joshi; Basavaraj Vastrad; Nidhi Joshi; Chanabasayya Vastrad; Anandkumar Tengli; Iranna Kotturshetti
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-24       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.